AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30579270
Drug: Convection-enhanced delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convection-enhanced delivery (CED) in the highest dose level.
Trial: 30579327
Drug: Viscoelastic tests-guided
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscoelastic tests-guided therapy with synthetic factor concentrates
Trial: 30580418
Drug: Mandibular repositioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular repositioning device (MRD) therapy
Trial: 30580723
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy + TOBT
Trial: 30580852
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant therapy (mainly vitamin K antagonist)
Trial: 30581606
Drug: Fludrocortisone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (0.4 mg per day for 7 days)
Trial: 30582166
Drug: Preoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antibiotic use (mean 27.8 ± 22.7 days out of 90 days prior to ESS)
Trial: 30582166
Drug: Increased preoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased preoperative antibiotic use
Trial: 30582166
Drug: Preoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antibiotic use
Trial: 30584308
Drug: Tigecycline (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (initial dose 100 mg, then 50 mg q12h)
Trial: 30584308
Drug: Imipenem/cilastatin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (500 mg/500 mg or adjusted for renal dysfunction, q6h)
Trial: 30585255
Drug: SAR405838 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR405838 200 mg QD plus pimasertib 45 mg BID
Trial: 30585255
Drug: SAR405838 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR405838 200 mg QD plus pimasertib 60 mg QD or 45 mg BID
Trial: 30586316
Drug: Sunitinib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib administered once weekly at 300 mg
Trial: 30586316
Drug: Sunitinib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib administered once every 2 weeks at 700 mg
Trial: 30586316
Drug: Sunitinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (both dosing schedules)
Trial: 30586316
Drug: Sunitinib (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (once every 2 weeks at 700 mg)
Trial: 30586692
Drug: Idarucizumab (5-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarucizumab (5-g dose administered as 2 bolus infusions of 2.5 g no more than 15 minutes apart)
Trial: 30588886
Drug: Chronic oral
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic oral anticoagulant therapy (OACb)
Trial: 30589495
Drug: tPA >20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA >20 ng/mL
Trial: 30589964
Drug: Bezafibrate add-on
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate add-on therapy
Trial: 30590596
Drug: Phylloquinone repletion
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phylloquinone repletion (∼500 µg phylloquinone/d)
Trial: 30590596
Drug: Phylloquinone depletion
RxNorm normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phylloquinone depletion (∼10 µg phylloquinone/d)
Trial: 30591285
Drug: Co-medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-medications
Trial: 30591548
Drug: DHEA 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 100 mg/day orally in combination with an aromatase inhibitor (AI)
Trial: 30591548
Drug: DHEA 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 100 mg/day orally
Trial: 30591982
Drug: Tarextumab 5
RxNorm normalized name: Tarextumab
DrugBank: Tarextumab (DB12104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarextumab 5 mg/kg weekly
Trial: 30591982
Drug: Tarextumab 10
RxNorm normalized name: Tarextumab
DrugBank: Tarextumab (DB12104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarextumab 10 mg/kg every other week
Trial: 30591982
Drug: Tarextumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarextumab 7.5 mg/kg every three weeks
Trial: 30591982
Drug: Tarextumab 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarextumab 2.5 mg/kg weekly
Trial: 30591982
Drug: Tarextumab 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarextumab 7.5 mg/kg every other week
Trial: 30591982
Drug: Tarextumab at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarextumab at doses <2.5 mg weekly and 7.5 mg/kg every other and every three weeks
Trial: 30593513
Drug: Lapatinib (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (first-line treatment for patients with CNS metastasis at diagnosis)
Trial: 30593513
Drug: Trastuzumab (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (first-line treatment for patients with CNS metastasis at diagnosis)
Trial: 30593776
Drug: Daily aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily aspirin use
Trial: 30596677
Drug: LivRelief Varicose
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LivRelief Varicose Vein Cream
Trial: 30596901
Drug: Multifaceted infection
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted infection prevention and control (IPC) bundle including IPC training, text message reminders, alcohol hand rub, enhanced environmental cleaning, and weekly bathing with 2% chlorhexidine gluconate.
Trial: 30597027
Drug: qPCR for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qPCR for G. vaginalis and/or Atopobium vaginae above a threshold
Trial: 30597509
Drug: Prolonged dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged dual anti-platelet therapy (DAPT)
Trial: 30598343
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (15-minute continuous infusion of native GLP-1 (7-36) NH)
Trial: 30598500
Drug: TKM-080301 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKM-080301 (0.3 mg/kg to 0.75 mg/kg, maximum tolerated dose redefined at 0.6 mg/kg)
Trial: 30598642
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg-equivalent dose regimens
Trial: 30600654
Drug: Live zoster
RxNorm normalized name: Varicella zoster vaccine (live/attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live zoster vaccine administered at 6-12 months after zoster illness
Trial: 30600654
Drug: Live zoster
RxNorm normalized name: Varicella zoster vaccine (live/attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live zoster vaccine administered at 1-5 years after zoster illness
Trial: 30603376
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal polysaccharide vaccine (23vPPV) during pregnancy
Trial: 30603378
Drug: Dexamethasone as
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone as adjunctive treatment
Trial: 30603797
Drug: Nintedanib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (150 mg or 200 mg oral twice daily) and Bevacizumab (15 mg/kg once intravenously every 3 weeks)
Trial: 30605211
Drug: Avelumab, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study.
Trial: 30605510
Drug: Inappropriate diagnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate diagnosis in a ventricular arrhythmia zone with enabled therapy
Trial: 30605510
Drug: Inappropriate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate therapy recurrence
Trial: 30605751
Drug: All dose
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dose levels (DL1, DL2, DL3)
Trial: 30606188
Drug: Physical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical and mental health symptom severity, psychiatric diagnosis, and psychopharmacological medication
Trial: 30606236
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation by oral administering
Trial: 30606236
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation through mid-gut transendoscopic enteral tubing (TET)
Trial: 30607301
Drug: Pressurized intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin aerosol, median 2 interventions per patient (range 1-6).
Trial: 30607629
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg once daily with trastuzumab 2 mg/kg and paclitaxel 80 mg/m²
Trial: 30607889
Drug: Milrinone continuous
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone continuous infusions
Trial: 30610196
Drug: Carfilzomib 36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib 36 mg/m² combined with panobinostat
Trial: 30610355
Drug: Postoperative radio(chemo)therapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radio(chemo)therapy
Trial: 30610872
Drug: Neurotropic drugs
RxNorm normalized name: neurotrophin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotropic drugs (including opioids, sedatives, hypnotics, antidepressants)
Trial: 30610872
Drug: Neurotropic drugs
RxNorm normalized name: neurotrophin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotropic drugs or cardiovascular drugs
Trial: 30611192
Drug: Subclinical tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subclinical tuberculosis treatment
Trial: 30611192
Drug: Active tuberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tuberculosis treatment
Trial: 30611197
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA, propofol + remifentanil)
Trial: 30611293
Drug: 2-HOBA acetate
RxNorm normalized name: 2-(Trimethylammonio)Acetate
DrugBank: 2-(aminomethyl)phenol (DB14855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-HOBA acetate (up to 825 mg)
Trial: 30612568
Drug: Standard oxaliplatin-based
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard oxaliplatin-based or irinotecan-based chemotherapy
Trial: 30612710
Drug: Sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200 mg, intravenous, once every 3 weeks)
Trial: 30612959
Drug: Hemostatic powder
RxNorm normalized name: collagen hemostat Topical Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemostatic powder (TC-325/Hemospray) applied as monotherapy in 13 bleeding sites (25%)
Trial: 30612959
Drug: Hemostatic powder
RxNorm normalized name: collagen hemostat Topical Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemostatic powder (TC-325/Hemospray) applied as combination therapy in 22 bleeding sites (42.3%)
Trial: 30612959
Drug: Hemostatic powder
RxNorm normalized name: collagen hemostat Topical Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemostatic powder (TC-325/Hemospray) applied as rescue therapy in 17 bleeding sites (32.7%)
Trial: 30614187
Drug: Circulating total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating total testosterone (TT) > 14.76 nmol/L
Trial: 30614187
Drug: Circulating total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circulating total testosterone (TT) ≤ 14.76 nmol/L
Trial: 30614939
Drug: Budesonide therapy
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide therapy (1 mg BID for 8 weeks)
Trial: 30616617
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for drug sensitive and multidrug-resistant pulmonary TB
Trial: 30616998
Drug: Dasatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100 mg/day) plus Quercetin (1250 mg/day), three-days/week over three-weeks
Trial: 30618179
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg once every 3 weeks for 2 years or until disease progression/unacceptable toxicity
Trial: 30618764
Drug: Fixed Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Combination of Chinese Herbal Medicine
Trial: 30618929
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen Therapy
Trial: 30619077
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Stimulation (FES) for gait rehabilitation, details on dosage and duration not available
Trial: 30619615
Drug: Micro-particle curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-particle curcumin 90 mg once daily for 6 months
Trial: 30621615
Drug: Option B+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Option B+ (antiretroviral therapy throughout life)
Trial: 30622509
Drug: Educational and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational and reminder-based intervention for adherence to direct oral anticoagulant treatment
Trial: 30622667
Drug: Atosiban (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (administered continuously for 48 hours)
Trial: 30623229
Drug: Intraperitoneal nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal nab-paclitaxel (IP) at a dose of 112.5 mg/m²
Trial: 30623229
Drug: Intraperitoneal nab-paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intraperitoneal nab-paclitaxel (IP) at doses 35-175 mg/m²
Trial: 30623276
Drug: ontuxizumab 2-12
RxNorm normalized name: Ontuxizumab
DrugBank: Ontuxizumab (DB16270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ontuxizumab 2-12 mg/kg weekly (part 1)
Trial: 30623276
Drug: ontuxizumab 4
RxNorm normalized name: Ontuxizumab
DrugBank: Ontuxizumab (DB16270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ontuxizumab 4 or 8 mg/kg weekly, or 12 mg/kg biweekly (part 2)
Trial: 30624149
Drug: Methylprednisolone group
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone group (MG, N = 18; 500 mg in the CPB priming)
Trial: 30624149
Drug: Methylprednisolone group
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone group (MG)
Trial: 30624546
Drug: Larotrectinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larotrectinib (100 mg twice daily)
Trial: 30624603
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g fish oil/d containing 1.9-2.2 g eicosapentaenoic acid and 1.1 g docosahexanoic acid for 6 weeks
Trial: 30624668
Drug: Colistin methanesulfonate
RxNorm normalized name: Colistin methanesulfonic acid
DrugBank: Colistimethate (DB01111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin methanesulfonate 6 million IU (MIU) loading dose followed by 3 MIU every 8 hours
Trial: 30626191
Drug: Technology-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology-based medication adherence support intervention (real-time adherence monitors linked to SMS text messages)
Trial: 30626633
Drug: hs-cTnT at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT at presentation >14 ng/L
Trial: 30626633
Drug: hs-cTnT at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT at presentation >52 ng/L
Trial: 30626633
Drug: Initial cTn
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial cTn concentrations alone and in combination with early changes
Trial: 30626746
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg mirtazapine daily for 7 days
Trial: 30629195
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) for 2 weeks
Trial: 30630355
Drug: Drug-Coated Balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Coated Balloon Treatment
Trial: 30630632
Drug: Low-grade inflammation
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-grade inflammation (CRP >1.0 mg/L to <10.0 mg/L)
Trial: 30630885
Drug: Atezolizumab in
RxNorm normalized name: atezolizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab in combination with paclitaxel, carboplatin, and bevacizumab
Trial: 30630885
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with paclitaxel, carboplatin, and bevacizumab
Trial: 30633573
Drug: Entospletinib 400
RxNorm normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entospletinib 400 mg BID
Trial: 30634942
Drug: Afatinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (30 mg) as add-on to gemcitabine/cisplatin (80% standard dose)
Trial: 30635165
Drug: Veliparib 40
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib 40 mg BID with gemcitabine 400 mg/m² and daily IMRT
Trial: 30635336
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of palbociclib (75 mg) and paclitaxel (80 mg/m2)
Trial: 30636101
Drug: hfTENS device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hfTENS device (Quell, NeuroMetrix, Inc.) used daily for 3 months
Trial: 30636249
Drug: Furosemide stress
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide stress test (FST) with a single dose of intravenous furosemide, 1.5 mg/kg at 3 h after allograft reperfusion
Trial: 30637118
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement with milk
Trial: 30637118
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement with food
Trial: 30637118
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement on an empty stomach
Trial: 30637118
Drug: Frozen fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frozen fish oil capsules prior to ingestion
Trial: 30637784
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow transplantation (BMT) with reduced toxicity preparative regimen of busulfan (13.2 mg/kg) and fludarabine (175 mg/m2)
Trial: 30638856
Drug: Burosumab (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burosumab (0.8 mg/kg) via subcutaneous injection every 2 weeks for 64 weeks, with possible increase to 1.2 mg/kg based on serum phosphorus levels.
Trial: 30640659
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (four incremental doses)
Trial: 30642285
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with 3 cycles of cisplatin and pemetrexed
Trial: 30642285
Drug: Metabolic responders
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metabolic responders on FDG-PET scan after chemotherapy
Trial: 30642285
Drug: Non-responders on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders on FDG-PET scan after chemotherapy
Trial: 30642290
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg IV every 4 weeks) and Tremelimumab (75 mg IV every 4 weeks for a total of 4 doses) with SBRT to 2-5 metastases